Scholarlink

Purpose <p>To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).</p> Methods/patients <p>A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan–Meier survival analysis.</p> Results <p>The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; <i>p</i> &lt; 0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095–0.724; <i>p</i> = 0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63&#xa0;months) and those who did not (47&#xa0;months), with a <i>p</i> value of 0.876.</p> Conclusions <p>BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月7日

查看全文
  • Manuel Sánchez Cánovas,
  • Javier López Robles,
  • Francisco José García Verdejo,
  • Diego Cacho Lavin,
  • Helena Olivares,
  • Alberto Garrido Fernández,
  • Eva Coma Salvans,
  • Teresa Quintanar Verduguez,
  • Carmen Salvador Coloma,
  • David Fernández Garay,
  • José David Cumplido,
  • Ana Isabel Ferrer Pérez,
  • Anna Carbó Bagué,
  • Francisco Javier Teigell Muñoz,
  • Ruben García López,
  • Andrea Martínez Marin,
  • Andrés J. Muñoz Martín

摘要

Purpose

To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).

Methods/patients

A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan–Meier survival analysis.

Results

The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; p < 0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095–0.724; p = 0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63 months) and those who did not (47 months), with a p value of 0.876.

Conclusions

BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.